Sikarin PCLBKK:SKR 90 ROE % is 6.38% as of Mar. 2026, which is 28% below its 10-year median of 8.87. GuruFocus rates BKK:SKR with a GF Score™ of 90/100 and a GF Value™ of ฿9.11 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 623 Healthcare Providers & Services companies, Sikarin PCL ranks better than 59.07% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Sikarin PCL's annualized net income for the quarter that ended in Mar. 2026 was ฿502 Mil. Sikarin PCL's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was ฿7,872 Mil. Therefore, Sikarin PCL's annualized ROE % for the quarter that ended in Mar. 2026 was 6.38%.
The historical rank and industry rank for Sikarin PCL's ROE % or its related term are showing as below:
BKK:SKR'
s ROE % Range Over the Past 10 Years
Min: 4.72 Med: 8.87 Max: 29.2
Current: 8.58
During the past 13 years, Sikarin PCL's highest ROE % was 29.20%. The lowest was 4.72%. And the median was 8.87%.
BKK:SKR's ROE % is ranked better than 59.07% of 623
companies
in the Healthcare Providers & Services industry
Industry Median: 5.86
vs BKK:SKR: 8.58
Sikarin PCL (BKK:SKR) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Sikarin PCL ROE % Related Terms
Sikarin PCL ROE % Historical Data
* Premium members only.
The historical data trend for Sikarin PCL's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Sikarin PCL's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sikarin PCL ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sikarin PCL's ROE % distribution charts can be found below:
* The bar in red indicates where Sikarin PCL's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Sikarin PCL (BKK:SKR) has a ROE % of 6.38% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Sikarin PCL and its competitors. This is 28% below median its historical median of 8.87. Over the past decade, Sikarin PCL's ROE % has ranged from 4.72 to 29.20. According to the industry distribution chart, Sikarin PCL ranks #255 out of 623 companies in the Healthcare Providers & Services industry, placing it in the top 40.9%.
Is Sikarin PCL's ROE % too high?
Sikarin PCL's current ROE % of 6.38% is 28% below median its 10-year median of 8.87. Over the past 10 years, this metric has ranged from a low of 4.72 to a high of 29.20. The Healthcare Providers & Services industry median ROE % is 5.86. Sikarin PCL's value of 6.38% is 8.9% above this industry median. Based on the distribution chart, Sikarin PCL ranks #255 out of 623 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Sikarin PCL has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sikarin PCL's ROE % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Sikarin PCL ranks #255 out of 623 companies for ROE %. This puts Sikarin PCL in the upper half of its industry. The industry median ROE % is 5.86. Sikarin PCL's value of 6.38% is 8.9% above this benchmark. Historically, Sikarin PCL's own ROE % has ranged from 4.72 to 29.20 over the past decade. While the company's 10-year median is 8.87 vs. the industry median of 5.86, Sikarin PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.86, based on 623 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sikarin PCL's current ROE % of 6.38% is 8.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Sikarin PCL and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sikarin PCL's current ROE % is 6.38%, which is 28% below median its own 10-year median of 8.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sikarin PCL stock overvalued right now?
Based on GuruFocus' analysis, Sikarin PCL (BKK:SKR) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿9.11, compared to a current price of ฿7.90 — trading 13.3% below its estimated fair value. The current ROE % is 6.38%, which is 28% below median its 10-year median of 8.87 and 8.9% above the Healthcare Providers & Services industry median of 5.86. Sikarin PCL's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Sikarin PCL (BKK:SKR), the current ROE % is 6.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sikarin PCL (BKK:SKR) Overvalued in 2026?
Based on GuruFocus' analysis, Sikarin PCL stock appears to be undervalued.
The current stock price of ฿7.90 is trading 13.3% below its estimated GF Value™ of ฿9.11.
GuruFocus considers Sikarin PCL to be Modestly Undervalued.
Key valuation signals for BKK:SKR:
ROE %: 6.38% (28% below median its 10-year median of 8.87)
GF Value™: ฿9.11 vs. price of ฿7.90 (13.3% below fair value)
Industry Position: 8.9% above the Healthcare Providers & Services median (#255 of 623)
No single metric tells the full story. See the BKK:SKR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSikarin PCL provides general healthcare services and operates under the social security system. The Group has one main operating segment, which is providing healthcare services through private hospitals and hospitals affiliated with the social security system. The Group operates in a single geographical area, which is Thailand. Its services include medical centers, a pediatric center, a women's institute, a radiology center, a neurology center, a rehabilitation center, and an orthopedic center.
90GF Score
Get the complete analysis for BKK:SKR
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:SKR has been successfully added to your 
